Blood sphingolipid as a novel biomarker in patients with neuromyelitis optica spectrum disorder-Reference-Cited by-同舟云学术

Blood sphingolipid as a novel biomarker in patients with neuromyelitis optica spectrum disorder

Published:2024-05 Issue: Volume:85 Page:105551
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Kim Hyunjin,Kim Hwa Jung,So Jungmin,Kim Ji Yon,Jung Hee-Jae,Kim Seungmi,Seo Dayoung,Kim Hyun-Ji,Song Ha Eun,Lim Young-Min,Yoo Hyun Ju,Lee Eun-Jae^ORCID

Funder

Korea Ministry of Science and ICT

Asan Institute for Life Sciences

Ministry of Science, ICT and Future Planning

Korean Neurological Association

Korea Ministry of Health and Welfare

Publisher

Elsevier BV

Reference35 articles.

1. Serum glial fibrillary acidic protein: a neuromyelitis optica spectrum disorder biomarker;Aktas;Ann. Neurol,2021

2. Lack of ceramide synthase 2 suppresses the development of experimental autoimmune encephalomyelitis by impairing the migratory capacity of neutrophils;Barthelmes;Brain Behav. Immun.,2015

3. Metabolic alterations in multiple sclerosis and the impact of vitamin D supplementation;Bhargava;JCI Insight,2017

4. A rapid method of total lipid extraction and purification;Bligh;Can. J. Biochem. Physiol,1959

5. Astrocytic ceramide as possible indicator of neuroinflammation;de Wit;J. Neuroinflammation,2019

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CSF sphingolipids are correlated with neuroinflammatory cytokines and differentiate neuromyelitis optica spectrum disorder from multiple sclerosis;Journal of Neurology, Neurosurgery & Psychiatry;2024-06-06